RVMD
Revolution Medicines, Inc.$185.71+0.78 (+0.42%)Prev Close$184.97·MCap$40.34B·P/E—·Vol629.0K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
48
$90.11M
◆
Net Activity
Net Seller
$90.11M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Revolution Medicines, Inc. (RVMD) has been exclusively selling, with 0 insider purchases totaling $0.00 and 48 insider sales totaling $90.11M. The most recent insider transaction was by Patel Sushil (director), who sold $994.0K worth of shares on Jul 1, 2026. Revolution Medicines, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $40.34B.
RVMD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Patel Sushil | director | Sell | 5,280 | $188.26 | $994.0K | 26,036 |
| Jun 26, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 20,000 | $168.33 | $3.37M | 138,716 |
| Jun 18, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 10,020 | $156.12 | $1.56M | 267,330 |
| Jun 18, 2026 | Mancini Anthony | officer: See Remarks | Sell | 4,615 | $156.12 | $720.5K | 49,975 |
| Jun 18, 2026 | Cislini Jeff | officer: General Counsel | Sell | 2,157 | $156.12 | $336.7K | 56,521 |
| Jun 18, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 2,722 | $156.12 | $425.0K | 123,269 |
| Jun 18, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 4,175 | $156.12 | $651.8K | 291,876 |
| Jun 17, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 93,575 | $160.00 | $14.97M | 158,222-37% |
| Jun 15, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 10,000 | $148.01 | $1.48M | 166,907 |
| May 28, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,121 | $153.99 | $480.6K | 56,821 |
| Apr 29, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,120 | $132.41 | $413.1K | 55,849 |
| Apr 17, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 120,000 | $150.09 | $18.01M | 276,698-30% |
| Mar 26, 2026 | Mancini Anthony | officer: See Remarks | Sell | 37,450 | $95.56 | $3.58M | 90,050-29% |
| Mar 19, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 2,753 | $99.48 | $273.9K | 125,512 |
| Mar 19, 2026 | Cislini Jeff | officer: General Counsel | Sell | 2,958 | $98.68 | $291.9K | 59,681 |
| Mar 19, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 12,871 | $99.48 | $1.28M | 276,698 |
| Mar 19, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 4,583 | $99.48 | $455.9K | 157,570 |
| Mar 19, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 4,302 | $99.48 | $428.0K | 295,398 |
| Mar 19, 2026 | Wang Xiaolin | officer: See Remarks | Sell | 2,010 | $99.48 | $200.0K | 116,063 |
| Mar 19, 2026 | Wei Lin | officer: Chief Medical Officer | Sell | 2,073 | $99.48 | $206.2K | 101,366 |
| Jan 21, 2026 | Cislini Jeff | General Counsel | Sell | 908 | $115.60 | $105.0K | 0 |
| Jan 9, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 73,300 | $100.51 | $7.37M | 162,957-31% |
| Jan 7, 2026 | Anders Jack | Chief Financial Officer | Sell | 10,000 | $98.00 | $980.0K | 0 |
| Jan 7, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 75,000 | $100.56 | $7.54M | 0 |
| Dec 16, 2025 | Anders Jack | Chief Financial Officer | Sell | 3,104 | $77.09 | $239.3K | 0 |
| Dec 16, 2025 | Cislini Jeff | General Counsel | Sell | 2,688 | $76.82 | $206.5K | 0 |
| Dec 16, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 15,394 | $76.82 | $1.18M | 0 |
| Dec 16, 2025 | Horn Margaret A | Chief Operating Officer | Sell | 4,847 | $76.82 | $372.3K | 0 |
| Dec 16, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 5,447 | $76.82 | $418.4K | 0 |
| Nov 25, 2025 | Anders Jack | Chief Financial Officer | Sell | 5,418 | $74.00 | $400.9K | 0 |
| Nov 25, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 63,000 | $75.08 | $4.73M | 0 |
| Nov 18, 2025 | Cislini Jeff | General Counsel | Sell | 13,388 | $70.14 | $939.0K | 0 |
| Nov 18, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 20,000 | $70.38 | $1.41M | 0 |
| Nov 12, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 20,000 | $65.07 | $1.30M | 0 |
| Nov 11, 2025 | Anders Jack | Chief Financial Officer | Sell | 10,000 | $64.00 | $640.0K | 0 |
| Nov 7, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 30,000 | $60.31 | $1.81M | 0 |
| Oct 17, 2025 | Cislini Jeff | General Counsel | Sell | 12,000 | $55.00 | $660.0K | 0 |
| Oct 16, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 20,000 | $52.74 | $1.05M | 0 |
| Oct 13, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 25,000 | $48.54 | $1.21M | 0 |
| Sep 24, 2025 | Cislini Jeff | General Counsel | Sell | 1,799 | $44.26 | $79.6K | 0 |
| Sep 16, 2025 | Anders Jack | Chief Financial Officer | Sell | 2,320 | $45.82 | $106.3K | 0 |
| Sep 16, 2025 | Cislini Jeff | General Counsel | Sell | 1,869 | $45.82 | $85.6K | 0 |
| Sep 16, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 13,411 | $45.82 | $614.6K | 0 |
| Sep 16, 2025 | Horn Margaret A | Chief Operating Officer | Sell | 4,775 | $45.82 | $218.8K | 0 |
| Sep 16, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 5,367 | $45.82 | $245.9K | 0 |
| Sep 16, 2025 | Wei Lin | Chief Medical Officer | Sell | 2,160 | $45.82 | $99.0K | 0 |
| Sep 11, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 125,000 | $44.46 | $5.56M | 0 |
| Sep 2, 2025 | Anders Jack | Chief Financial Officer | Sell | 10,000 | $40.10 | $401.0K | 0 |
| Jun 20, 2025 | Cislini Jeff | General Counsel | Sell | 1,912 | $39.61 | $75.7K | 0 |
| Jun 16, 2025 | Anders Jack | Chief Financial Officer | Sell | 2,170 | $39.83 | $86.4K | 0 |
Showing 1–50 of 198
1 / 4
RVMD Insider Buying Activity
The following table shows recent insider purchases of Revolution Medicines, Inc. (RVMD) stock reported via SEC Form 4 filings.
No insider buying activity found for RVMD in the last 12 months.
RVMD Insider Selling Activity
The following table shows recent insider sales of Revolution Medicines, Inc. (RVMD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Patel Sushil | director | Sell | 5,280 | $188.26 | $994.0K | 26,036 |
| Jun 26, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 20,000 | $168.33 | $3.37M | 138,716 |
| Jun 18, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 10,020 | $156.12 | $1.56M | 267,330 |
| Jun 18, 2026 | Mancini Anthony | officer: See Remarks | Sell | 4,615 | $156.12 | $720.5K | 49,975 |
| Jun 18, 2026 | Cislini Jeff | officer: General Counsel | Sell | 2,157 | $156.12 | $336.7K | 56,521 |
| Jun 18, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 2,722 | $156.12 | $425.0K | 123,269 |
| Jun 18, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 4,175 | $156.12 | $651.8K | 291,876 |
| Jun 17, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 93,575 | $160.00 | $14.97M | 158,222-37% |
| Jun 15, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 10,000 | $148.01 | $1.48M | 166,907 |
| May 28, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,121 | $153.99 | $480.6K | 56,821 |
| Apr 29, 2026 | Mancini Anthony | officer: See Remarks | Sell | 3,120 | $132.41 | $413.1K | 55,849 |
| Apr 17, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 120,000 | $150.09 | $18.01M | 276,698-30% |
| Mar 26, 2026 | Mancini Anthony | officer: See Remarks | Sell | 37,450 | $95.56 | $3.58M | 90,050-29% |
| Mar 19, 2026 | Anders Jack | officer: Chief Financial Officer | Sell | 2,753 | $99.48 | $273.9K | 125,512 |
| Mar 19, 2026 | Cislini Jeff | officer: General Counsel | Sell | 2,958 | $98.68 | $291.9K | 59,681 |
| Mar 19, 2026 | GOLDSMITH MARK A | director, officer: See Remarks | Sell | 12,871 | $99.48 | $1.28M | 276,698 |
| Mar 19, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 4,583 | $99.48 | $455.9K | 157,570 |
| Mar 19, 2026 | Kelsey Stephen Michael | officer: See Remarks | Sell | 4,302 | $99.48 | $428.0K | 295,398 |
| Mar 19, 2026 | Wang Xiaolin | officer: See Remarks | Sell | 2,010 | $99.48 | $200.0K | 116,063 |
| Mar 19, 2026 | Wei Lin | officer: Chief Medical Officer | Sell | 2,073 | $99.48 | $206.2K | 101,366 |
| Jan 21, 2026 | Cislini Jeff | General Counsel | Sell | 908 | $115.60 | $105.0K | 0 |
| Jan 9, 2026 | Horn Margaret A | officer: Chief Operating Officer | Sell | 73,300 | $100.51 | $7.37M | 162,957-31% |
| Jan 7, 2026 | Anders Jack | Chief Financial Officer | Sell | 10,000 | $98.00 | $980.0K | 0 |
| Jan 7, 2026 | Horn Margaret A | Chief Operating Officer | Sell | 75,000 | $100.56 | $7.54M | 0 |
| Dec 16, 2025 | Anders Jack | Chief Financial Officer | Sell | 3,104 | $77.09 | $239.3K | 0 |
| Dec 16, 2025 | Cislini Jeff | General Counsel | Sell | 2,688 | $76.82 | $206.5K | 0 |
| Dec 16, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 15,394 | $76.82 | $1.18M | 0 |
| Dec 16, 2025 | Horn Margaret A | Chief Operating Officer | Sell | 4,847 | $76.82 | $372.3K | 0 |
| Dec 16, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 5,447 | $76.82 | $418.4K | 0 |
| Nov 25, 2025 | Anders Jack | Chief Financial Officer | Sell | 5,418 | $74.00 | $400.9K | 0 |
| Nov 25, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 63,000 | $75.08 | $4.73M | 0 |
| Nov 18, 2025 | Cislini Jeff | General Counsel | Sell | 13,388 | $70.14 | $939.0K | 0 |
| Nov 18, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 20,000 | $70.38 | $1.41M | 0 |
| Nov 12, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 20,000 | $65.07 | $1.30M | 0 |
| Nov 11, 2025 | Anders Jack | Chief Financial Officer | Sell | 10,000 | $64.00 | $640.0K | 0 |
| Nov 7, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 30,000 | $60.31 | $1.81M | 0 |
| Oct 17, 2025 | Cislini Jeff | General Counsel | Sell | 12,000 | $55.00 | $660.0K | 0 |
| Oct 16, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 20,000 | $52.74 | $1.05M | 0 |
| Oct 13, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 25,000 | $48.54 | $1.21M | 0 |
| Sep 24, 2025 | Cislini Jeff | General Counsel | Sell | 1,799 | $44.26 | $79.6K | 0 |
| Sep 16, 2025 | Anders Jack | Chief Financial Officer | Sell | 2,320 | $45.82 | $106.3K | 0 |
| Sep 16, 2025 | Cislini Jeff | General Counsel | Sell | 1,869 | $45.82 | $85.6K | 0 |
| Sep 16, 2025 | GOLDSMITH MARK A | See Remarks | Sell | 13,411 | $45.82 | $614.6K | 0 |
| Sep 16, 2025 | Horn Margaret A | Chief Operating Officer | Sell | 4,775 | $45.82 | $218.8K | 0 |
| Sep 16, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 5,367 | $45.82 | $245.9K | 0 |
| Sep 16, 2025 | Wei Lin | Chief Medical Officer | Sell | 2,160 | $45.82 | $99.0K | 0 |
| Sep 11, 2025 | Kelsey Stephen Michael | See Remarks | Sell | 125,000 | $44.46 | $5.56M | 0 |
| Sep 2, 2025 | Anders Jack | Chief Financial Officer | Sell | 10,000 | $40.10 | $401.0K | 0 |
| Jun 20, 2025 | Cislini Jeff | General Counsel | Sell | 1,912 | $39.61 | $75.7K | 0 |
| Jun 16, 2025 | Anders Jack | Chief Financial Officer | Sell | 2,170 | $39.83 | $86.4K | 0 |
RVMD Insiders
Similar Stocks to RVMD
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B
NBIX
Neurocrine Biosciences, Inc.
$170.83-0.71%
$17.81B